This article was originally published in The Gray Sheet
Raises approximately $11.6 mil. in gross proceeds through its direct placement "principally to selected investors" of 4.9 mil. securities. The securities consist of 4.9 mil. shares of common stock and 4.9 mil. 18-month warrants. If the warrants are exercised, Angeion will raise additional gross proceeds of $11.6 mil. Net proceeds will be used to fund company research and development, purchase equipment, and to repay short-term bridge loans, the firm says. Plymouth, Minnesota-based Angeion is developing the Sentinel 2000 new-generation implantable cardioverter defibrillator and catheter ablation systems
You may also be interested in...
Siemens Healthineers' product mix of diagnostics and imaging products meant it was in the middle of a very dynamic situation when COVID-19 struck.
The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.